An observational study in Ankylosing Spondylitis, sponsored by AbbVie. Completed at 61 sites in Japan. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by AbbVie · Observational
Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. This study will assess how effective Rinvoq is in treating axSpA.
Rinvoq is an approved drug for treating axSpA. Approximately 100 adult participants who are prescribed Rinvoq by their physician in accordance with local label will be enrolled in Japan.
Participants will receive Rinvoq as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 52 weeks.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
498 studies on the registry are indexed under Spondylitis, Ankylosing; 89 are open to participants now.
This study's enrollment of 69 is below the median of 200 across 210 observational studies indexed under Spondylitis, Ankylosing.
Browse Spondylitis, Ankylosing studies →AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.
Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult participants with Ankylosing Spondylitis (AS)
Exclusion Criteria:
Participants will receive Rinvoq as prescribed by their physician according to local label.
Incidence Percentage of Serious Infection as Adverse Drug Reactions ( ADR)
Incidence of serious drug related adverse reactions will be assessed.
Time frame: Up to 52 Weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie